February 15, 2017
(Science Daily) – University of Tübingen researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine. For the trial, Pro-fessor Peter Kremsner and Dr. Benjamin Mordmüller of the Institute of Tropical Medicine and the German Center for Infection Research (DZIF) used malaria parasites provided by Sanaria. The vac-cine incorporated fully viable — not weakened or otherwise inactivated — malaria pathogens together with the medication to combat them. Their research results have been published in the latest edition of Nature.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.